Projected Out-of-Pocket Savings of the Medicare Part D $2 Drug List Model
This study evaluates the amount of out-of-pocket cost savings Medicare Part D beneficiaries would have experienced if a proposed Medicare $2 drug list model had been in place in 2021.
This study evaluates the amount of out-of-pocket cost savings Medicare Part D beneficiaries would have experienced if a proposed Medicare $2 drug list model had been in place in 2021.
